Results released
Open the filing on sec.gov
Yarrow Bioscience, Inc. (YARW)
Nasdaq: YARW · Bridgewater, NJ · filing with the SEC since 2013
The companyfiscal 2025, as filed
Revenue$570,000+13.8%
Net income-$26.5M+33.5%
Earnings per share$-0.62+33.3%
Operating cash flow-$33.1M+2.5%
Cash$24.0M+20.6%
Debt$0.00
Shareholders’ equity$27.8M-46.7%
Shares, diluted42.8M+0.4%
Return on equity-95.4%
The recordfrom its filings
Filings in 202683
Newest filingNov 12 · 8-K
Annual reportFeb 27, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted20
Filer categoryNon-accelerated filer<br>Smaller reporting company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.